Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the GLP-1 hormone to manage type 2 diabetes and promote significant weight loss. By reducing appetite, slowing gastric emptying, and enhancing insulin secretion, it aids in long-term weight management and lowers risks of cardiovascular events. It is sold under brands like Ozempic, Wegovy, and Rybelsus.
Mechanism of Action
- Appetite Suppression: Semaglutide mimics natural GLP-1, targeting brain receptors to increase feelings of fullness and reduce hunger.
- Blood Sugar Regulation: It prompts the pancreas to release more insulin when blood sugar levels are high and prevents the liver from releasing too much glucose.
- Gastric Emptying: It slows the rate at which the stomach empties food, which keeps the user feeling full longer.
Common Uses
- Type 2 Diabetes: Used alongside diet and exercise to manage blood sugar.
- Weight Loss/Management: Approved for chronic weight management in patients with obesity or overweight.
- Cardiovascular Health: Reduces the risk of major adverse cardiovascular events (e.g., heart attack, stroke) in patients with diabetes or weight-related conditions.
Administration and Brands
- Ozempic (Injectable): Subcutaneous, once-weekly injection for type 2 diabetes and cardiovascular risk reduction.
- Wegovy (Injectable): Subcutaneous, once-weekly injection specifically approved for chronic weight management.
